- Home
- MYNZ vs CVKD Comparison
MYNZ vs CVKD Comparison
Compare MYNZ & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- CVKD
- Stock Information
- Founded
- MYNZ 2021
- CVKD 2022
- Country
- MYNZ Germany
- CVKD United States
- Employees
- MYNZ N/A
- CVKD N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- MYNZ Health Care
- CVKD Health Care
- Exchange
- MYNZ Nasdaq
- CVKD Nasdaq
- Market Cap
- MYNZ 5.5M
- CVKD 29.5M
- IPO Year
- MYNZ 2021
- CVKD 2023
- Fundamental
- Price
- MYNZ $1.44
- CVKD $12.80
- Analyst Decision
- MYNZ Buy
- CVKD Strong Buy
- Analyst Count
- MYNZ 2
- CVKD 1
- Target Price
- MYNZ $14.00
- CVKD $32.00
- AVG Volume (30 Days)
- MYNZ 119.0K
- CVKD 32.3K
- Earning Date
- MYNZ 07-15-2025
- CVKD 08-06-2025
- Dividend Yield
- MYNZ N/A
- CVKD N/A
- EPS Growth
- MYNZ N/A
- CVKD N/A
- EPS
- MYNZ N/A
- CVKD N/A
- Revenue
- MYNZ $893,991.00
- CVKD N/A
- Revenue This Year
- MYNZ $26.06
- CVKD N/A
- Revenue Next Year
- MYNZ $4.97
- CVKD N/A
- P/E Ratio
- MYNZ N/A
- CVKD N/A
- Revenue Growth
- MYNZ N/A
- CVKD N/A
- 52 Week Low
- MYNZ $1.34
- CVKD $5.70
- 52 Week High
- MYNZ $22.40
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- MYNZ 26.61
- CVKD 49.60
- Support Level
- MYNZ $1.35
- CVKD $11.00
- Resistance Level
- MYNZ $1.46
- CVKD $13.71
- Average True Range (ATR)
- MYNZ 0.12
- CVKD 1.14
- MACD
- MYNZ 0.02
- CVKD 0.10
- Stochastic Oscillator
- MYNZ 9.27
- CVKD 63.54
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.